Barclays PLC Buys 18,724 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

Barclays PLC grew its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 106.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,296 shares of the biotechnology company's stock after acquiring an additional 18,724 shares during the period. Barclays PLC owned 0.08% of Capricor Therapeutics worth $552,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. SG Americas Securities LLC bought a new position in Capricor Therapeutics during the third quarter worth $133,000. Bank of New York Mellon Corp raised its holdings in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock valued at $381,000 after purchasing an additional 9,040 shares during the period. The Manufacturers Life Insurance Company bought a new position in shares of Capricor Therapeutics during the 3rd quarter worth about $161,000. Sassicaia Capital Advisers LLC bought a new position in shares of Capricor Therapeutics during the 3rd quarter worth about $192,000. Finally, Oppenheimer & Co. Inc. grew its stake in shares of Capricor Therapeutics by 25.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company's stock valued at $1,040,000 after buying an additional 13,762 shares during the period. 21.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CAPR shares. HC Wainwright reaffirmed a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday, January 2nd. Oppenheimer reissued an "outperform" rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Piper Sandler started coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They set an "overweight" rating and a $35.00 price objective on the stock. Maxim Group raised their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. Finally, Cantor Fitzgerald boosted their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $34.50.

Capricor Therapeutics Price Performance

Shares of CAPR stock traded up $0.20 on Friday, hitting $13.70. The stock had a trading volume of 688,914 shares, compared to its average volume of 1,075,567. The business has a 50 day moving average of $15.46 and a 200 day moving average of $11.55. Capricor Therapeutics Inc has a 12-month low of $3.52 and a 12-month high of $23.40. The stock has a market cap of $622.94 million, a price-to-earnings ratio of -12.92 and a beta of 4.08.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.